Provided by Tiger Fintech (Singapore) Pte. Ltd.

Unity Biotechnology

0.7980
-0.0579-6.76%
Post-market: 0.7860-0.0120-1.50%17:58 EDT
Volume:168.40K
Turnover:136.80K
Market Cap:13.74M
PE:-0.49
High:0.8559
Open:0.8300
Low:0.7950
Close:0.8559
Loading ...

Unity Biotechnology Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
27 May

Unity Biotechnology: Hold Rating Amid Leadership Changes and Mixed UBX1325 Study Results

TIPRANKS
·
27 May

Unity Biotechnology downgraded to Neutral from Buy at H.C. Wainwright

TIPRANKS
·
27 May

UNITY Biotechnology Inc : Mizuho Cuts to Neutral From Outperform, Cuts Target Price to $1 From $6

THOMSON REUTERS
·
19 May

Mizuho Downgrades Unity Biotechnology to Neutral From Outperform After Diabetic Edema Treatment Misses Primary Endpoint, Cuts Price Target to $1 From $6

MT Newswires Live
·
16 May

UNITY Biotechnology Inc : Mizuho Cuts to Neutral From Outperform; Cuts Target Price to $1 From $6

THOMSON REUTERS
·
16 May

Unity Biotechnology Explores Strategic Alternatives Post-ASPIRE Study

TIPRANKS
·
05 May

BRIEF-UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force

Reuters
·
05 May

UNITY Biotechnology Inc - Reduction in Force Expected to Be Completed by May 15, 2025 - SEC Filing

THOMSON REUTERS
·
05 May

UNITY Biotechnology Inc - CEO Anirvan Ghosh, CFO Lynne Sullivan, and Alexander Nguyen to Terminate Employment - SEC Filing

THOMSON REUTERS
·
05 May

UNITY Biotechnology: to Explore Strategic Alternatives to Advance Ubx1325, Tie2/Anti-Vegf Bispecific, & Tie2 Agonistic Antibody Assets

THOMSON REUTERS
·
05 May

UNITY Biotechnology Announces Complete 36-Week Results From the Aspire Phase 2B Study of Ubx1325 in Diabetic Macular Edema and Provides Corporate Updates

THOMSON REUTERS
·
05 May

UNITY Biotechnology Inc - Board Approves Revised Operating Plan to Reduce Cash Burn

THOMSON REUTERS
·
05 May

UNITY Biotechnology - to Implement Workforce Reduction and Consulting Arrangements in Place to Close Down Aspire Study

THOMSON REUTERS
·
05 May

UNITY Biotechnology Inc - CEO, CFO, and Clo to Transition Into Consulting Roles

THOMSON REUTERS
·
05 May

UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates

GlobeNewswire
·
05 May

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

GlobeNewswire
·
01 May

Unity Biotechnology Is Maintained at Buy by Chardan Capital

Dow Jones
·
23 Apr

UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME

GlobeNewswire
·
23 Apr

Unity Biotechnology Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
23 Apr